Please assess the completion status of the following clinical trial:

Trial Title: Intravenous CTLA4-lg Treatment in Recent Onset Type 1 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 6-45~2. Within 3 months (100 days) of diagnosis of T1DM based on ADA criteria~3. At least one diabetes-related autoantibody~4. Stimulated C-peptide level \>0.2 pmol/ml by MMTT conducted 21 days after diagnosis of T1DM and within 37 days of randomization~5. At least three months from last live immunization received and willing to forgo live vaccinations for three months following last dose of study treatment~Exclusion Criteria:~1. Immunodeficiency, chronic lymphopenia, active infection, positive PPD result or a history of malignancy~2. Serologic evidence of current or past HIV, Hepatitis B or C~3. Pregnancy, lactation, or intention of pregnancy while on study~4. Current use of immunosuppressive agents, or medications known to influence glucose tolerance or glycemic control~5. Current participation in another T1DM treatment study

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Intravenous infusions of CTLA-4 Ig
- 2 (Type: PLACEBO_COMPARATOR): Intravenous infusions of placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).